Biosimilars: Is Small Dip In Development Indicative Of Sustained Downward Trend?
Executive Summary
As US FDA sees dip in application development, experts offer contrasting assessments about future of biosimilars at AAM's GRx Biosims conference.
You may also be interested in...
Pfizer Wants FDA To Stop Sponsor Promos From Implying Biosimilars Are Inferior
Citizen petition requests agency guidance that specifies what communications are false and misleading; Pfizer cites a Janssen Remicade brochure and Amgen YouTube video that suggest switching to biosimilars could lead to different outcomes.
Interchangeability Won’t Solve US Biosimilar Market’s Woes, FDA’s Gottlieb Says
FDA's Biosimilar Action Plan aims to boost approvals, but Commissioner Gottlieb says he's had a change of heart about how much impact an interchangeability designation can have on market uptake.
Biosimilars For US Market May Be Able To Rely On EU-Licensed Reference Products
Commissioner Scott Gottlieb says move could allow biosimilar sponsors to avoid anti-competitive efforts by brand sponsors in US.